Send us a Message



 Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap)  (beta) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer) Overgo Probe Designer
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease COVID-19 Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models PhenoMiner (Quantitative Phenotypes) Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Poster Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor
go back to main search page
Accession:CHEBI:76835 term browser browse the term
Definition:An EC 1.1.* (oxidoreductase acting on donor CH-OH group) inhibitor that uses NAD(+) or NADP(+) as acceptor (EC 1.1.1.*).
Synonyms:related_synonym: EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+)acceptor) inhibitors;   EC 1.1.1.* inhibitor;   EC 1.1.1.* inhibitors


show annotations for term's descendants           Sort by:
1,2-dihexadecanoyl-sn-glycero-3-phosphocholine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G PLCG1 phospholipase C gamma 1 decreases activity
multiple interactions		 EXP 1,2-Dipalmitoylphosphatidylcholine results in decreased activity of PLCG1 protein
dipalmitoylphosphatidic acid inhibits the reaction [1,2-Dipalmitoylphosphatidylcholine results in decreased activity of PLCG1 protein]		 CTD PMID:2001791 NCBI chr24:29,198,536...29,213,899
Ensembl chr24:29,198,556...29,214,714 		JBrowse link
acetylsalicylic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G PTGS1 prostaglandin-endoperoxide synthase 1 decreases activity EXP Aspirin results in decreased activity of PTGS1 protein alternative form CTD PMID:12242329 NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819 		JBrowse link
dihexadecanoyl phosphatidic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G PLCG1 phospholipase C gamma 1 multiple interactions
increases activity		 EXP dipalmitoylphosphatidic acid inhibits the reaction [1,2-Dipalmitoylphosphatidylcholine results in decreased activity of PLCG1 protein]
dipalmitoylphosphatidic acid results in increased activity of PLCG1 protein		 CTD PMID:2001791 NCBI chr24:29,198,536...29,213,899
Ensembl chr24:29,198,556...29,214,714 		JBrowse link
fomepizole term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP2E1 cytochrome P450 family 2 subfamily E member 1 multiple interactions EXP Fomepizole inhibits the reaction [CYP2E1 protein affects the metabolism of Toluene] CTD PMID:8592870 NCBI chr28:41,079,164...41,089,188
Ensembl chr28:41,035,025...41,122,754 		JBrowse link
pitavastatin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G NCF1 neutrophil cytosolic factor 1 decreases expression EXP pitavastatin results in decreased expression of NCF1 mRNA CTD PMID:15502390 NCBI chr 6:5,702,222...5,719,515
Ensembl chr 6:5,605,694...5,719,458 		JBrowse link
G NOS3 nitric oxide synthase 3 increases activity
increases expression		 EXP pitavastatin results in increased activity of NOS3 protein
pitavastatin results in increased expression of NOS3 mRNA		 CTD PMID:15502390 NCBI chr16:15,054,196...15,072,454
Ensembl chr16:15,011,344...15,072,277 		JBrowse link
G NOX4 NADPH oxidase 4 decreases expression EXP pitavastatin results in decreased expression of NOX4 mRNA CTD PMID:15502390 NCBI chr21:10,615,153...10,782,927
Ensembl chr21:10,615,970...10,775,277 		JBrowse link
simvastatin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G NOS3 nitric oxide synthase 3 increases expression
decreases expression		 EXP Simvastatin results in increased expression of NOS3 protein
Simvastatin results in decreased expression of NOS3 mRNA		 CTD PMID:11087217 NCBI chr16:15,054,196...15,072,454
Ensembl chr16:15,011,344...15,072,277 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 404
    role 404
      biological role 404
        biochemical role 363
          enzyme inhibitor 273
            EC 1.* (oxidoreductase) inhibitor 29
              EC 1.1.* (oxidoreductase acting on donor CH-OH group) inhibitor 9
                EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor 6
                  EC 1.1.1.1 (alcohol dehydrogenase) inhibitor + 1
                  EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor + 0
                  EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor + 0
                  EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor + 0
                  EC 1.1.1.159 (7alpha-hydroxysteroid dehydrogenase) inhibitor + 0
                  EC 1.1.1.170 [3beta-hydroxysteroid-4alpha-carboxylate 3-dehydrogenase (decarboxylating)] inhibitor + 0
                  EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor + 0
                  EC 1.1.1.188 (prostaglandin-F synthase) inhibitor + 1
                  EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor + 1
                  EC 1.1.1.205 (IMP dehydrogenase) inhibitor + 0
                  EC 1.1.1.21 (aldehyde reductase) inhibitor + 0
                  EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor + 0
                  EC 1.1.1.25 (shikimate dehydrogenase) inhibitor + 0
                  EC 1.1.1.267 (1-deoxy-D-xylulose-5-phosphate reductoisomerase) inhibitor + 0
                  EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor + 3
                  EC 1.1.1.37 (malate dehydrogenase) inhibitor + 0
                  EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor + 0
                  EC 1.1.1.44 (NADP(+)-dependent decarboxylating phosphogluconate dehydrogenase) inhibitor + 0
paths to the root